首页> 外文期刊>Vaccine >Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines
【24h】

Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines

机译:冷适应的X-31减毒活大流行H5N1流感疫苗的免疫原性和保护功效

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Despite global efforts to control influenza viruses, they have taken a heavy toll on human public health worldwide. Among particular threats is highly pathogenic avian H5N1 influenza virus (HPAI) due to not only its high mortality in humans but also possible human-to-human transmission either through reassortment with other human influenza viruses such as 2009 pandemic H1N1 influenza virus, or by genetic mutations. With the aim of developing effective vaccines against the H5N1 viruses, we generated two live attenuated H5N1 vaccine candidates against A/Indonesia/05/2005 (clade 2.1) and A/chicken/Korea/ES/2003 (clade 2.5) strains, in the genetic background of the cold-adapted donor strain of X-31. In mice, a single dose of immunization with each of the two vaccines was highly immunogenic inducing high titers of serum viral-neutralizing and hemagglutinin-inhibiting antibodies against the homologous H5N1 strain. Furthermore, significant levels of cross-clade antibody responses were induced by the vaccines, suggesting a broad-spectrum cross-reactivity against the heterologous H5N1 strains. The immunizations provided solid protections against heterologous lethal challenges with H5N2 virus, significantly reducing the morbidity and challenge virus replications in the respiratory tracts. The robustness of the antibody responses against both the homologous and heterologous strains, together with efficient protection against the lethal H5N2 challenge, strongly support the protection against wild type H5N1 infections. These results could serve as an experimental basis for the development of safe and effective H5N1 pre-pandemic vaccines while further addressing the biosecurity concerns associated with H5N1 HPAI
机译:尽管在全球范围内努力控制流感病毒,但它们对全世界的人类公共健康造成了沉重的损失。高致病性禽流感H5N1流感病毒(HPAI)尤其具有威胁性,这不仅是由于其在人类中的高死亡率,而且还可能通过与其他人类流感病毒(例如2009大流行H1N1流感病毒)的重配或人与人之间的传播突变。为了开发针对H5N1病毒的有效疫苗,我们在大肠杆菌中产生了两种针对A / Indonesia / 05/2005(clade 2.1)和A / chicken / Korea / ES / 2003(clade 2.5)的减毒活H5N1候选疫苗。 X-31供体冷适应株的遗传背景。在小鼠中,用两种疫苗中的每一种进行单次免疫均具有高免疫原性,可诱导高滴度的针对同源H5N1株的血清病毒中和和血凝素抑制抗体。此外,疫苗诱导了显着水平的交叉抗体反应,这表明针对异源H5N1菌株具有广谱交叉反应性。免疫接种提供了针对H5N2病毒的异源致死性攻击的可靠保护,可显着降低发病率和攻击性病毒在呼吸道中的复制。针对同源和异源菌株的抗体反应的稳健性,以及针对致命H5N2攻击的有效保护,强烈支持了针对野生型H5N1感染的保护。这些结果可作为开发安全有效的H5N1大流行前疫苗的实验基础,同时进一步解决与H5N1 HPAI相关的生物安全问题

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号